Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i> -Mutant Metastatic Non–Small Cell Lung Cancer — Sandra Ortiz‐Cuaran (2020) | RDL Network
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i> -Mutant Metastatic Non–Small Cell Lung Cancer
Article 2020 en
Authors
SO
Sandra Ortiz‐Cuaran
LM
Laura Mezquita
AS
Aurélie Swalduz
Abstract
1 min read
ctDNA sequencing is clinically relevant for the detection of <i>BRAF</i>-activating mutations and the identification of alterations potentially related to resistance to BRAF-TT in <i>BRAF</i>-mutant NSCLC.
Shahneen Sandhu, Stephen Q. Wong, Ismael A. Vergara, Jeanette Raleigh, Jason Callahan, Sarah Ftouni, Athena Hatzimihalis, Devbarna Sinha, Ken Doig, Andrew J. Colebatch, Gisela Mir-Arnau, Carleen Cullinane, David Gyorki, Damien Kee, Benjamin Brady, Mark Shackleton, Anthony T. Papenfuss, Rodney J. Hicks, Grant A. McArthur, Sarah‐Jane Dawson
Elin S. Gray, Helen Rizos, Anna Reid, Suzanah C. Boyd, Michelle R. Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard A Scolyer, Kelvin Shenq Woei Siew, Chris Lomma, Adam Cooper, Muhammad A. Khattak, Tarek Meniawy, Georgina V. Long, Matteo S. Carlino, Michael Millward, Mel Ziman
Russell J. Diefenbach, Jenny Lee, Dario Strbenac, Jean Yang, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Andrew J. Spillane, Jonathan R. Stretch, Robyn P.M. Saw, John F. Thompson, Sydney Ch’ng, Richard A Scolyer, Richard Kefford, Helen Rizos
Discussion(0)
No comments yet. Be the first to comment.